Pilot study of repetitive transcranial magnetic stimulation in patients with chemotherapy-induced peripheral neuropathy

被引:11
作者
Goto, Yuko [1 ,2 ,3 ]
Hosomi, Koichi [1 ,2 ]
Shimokawa, Toshio [4 ]
Shimizu, Takeshi [5 ]
Yoshino, Kiyoshi [6 ]
Kim, Seung Jin [7 ]
Mano, Tomoo [1 ]
Kishima, Haruhiko [2 ]
Saitoh, Youichi [1 ,2 ]
机构
[1] Osaka Univ, Dept Neuromodulat, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Neurosurg, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[3] Yu Neurosurg Clin, Toyonaka, Osaka 5600083, Japan
[4] Wakayama Med Univ, Clin Study Support Ctr, Wakayama, Wakayama 6418509, Japan
[5] Kansai Rosai Hosp, Dept Neurosurg, Amagasaki, Hyogo 6608511, Japan
[6] Univ Occupat & Environm Hlth, Grad Sch Med, Dept Obstet & Gynecol, Kitakyushu, Fukuoka, Japan
[7] Osaka Univ, Dept Breast & Endocrine Surg, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
Repetitive transcranial magnetic stimulation; Chemotherapy-induced peripheral neuropathy; Primary motor cortex; PRIMARY MOTOR CORTEX; QUALITY-OF-LIFE; DOUBLE-BLIND; PAIN RELIEF; RTMS; CROSSOVER; SURVIVORS;
D O I
10.1016/j.jocn.2020.01.020
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the intractable long-term side effects of anticancer medications and results in pain and dysesthesia. Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex has been demonstrated to provide effective relief for intractable neuropathic pain. The objective of this study was to investigate the effects of rTMS treatment on CIPN in cancer patients. Materials and methods: Eleven female patients with breast cancer or gynecologic cancer (mean age 64.8 [standard deviation 7.8]) who had neuropathic pain and/or peripheral sensory neuropathy, with a minimum two grade severity based on the scale of the National Cancer Institutes' Common Terminology Criteria for Adverse Events (version 4.0) were enrolled. Patients received rTMS (5-Hz; 500 pulses/session; figure-8 coil) on their primary motor cortex corresponding to the target extremity. The intensity of pain and dysesthesia for all extremities was evaluated using a visual analog scale for pain, dysesthesia, and the Japanese version of the short-form McGill Pain Questionnaire 2 (SFMPQ2). Results: rTMS for target extremity significantly decreased the visual analog scale of pain and dysesthesia. The intensity of pain measured by the SFMPQ2 was also decreased in the target extremity. Regarding non-target extremities, only dysesthesia significantly decreased as a result of rTMS. No adverse events were observed. Conclusion: This is an initial report demonstrating the potential of rTMS for the treatment of CIPN. We suggest rTMS could be potentially beneficial and effective as a treatment for pain and dysesthesia in patients with CIPN. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 50 条
  • [41] Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience
    Oneda, Ester
    Meriggi, Fausto
    Zanotti, Laura
    Zaina, Elisabetta
    Bighe, Sara
    Andreis, Federica
    Rueda, Sabogal
    Zaniboni, Alberto
    INTEGRATIVE CANCER THERAPIES, 2020, 19
  • [42] REPETITIVE PERIPHERAL MAGNETIC STIMULATION COMBINED WITH TRANSCRANIAL MAGNETIC STIMULATION IN REHABILITATION OF UPPER EXTREMITY HEMIPARESIS FOLLOWING STROKE: A PILOT STUDY
    Liang, Sijie
    Wang, Weining
    Yu, Fengyun
    Pan, Li
    Xu, Dongyan
    Hu, Ruiping
    Tian, Shan
    Xiang, Jie
    Zhu, Yulian
    JOURNAL OF REHABILITATION MEDICINE, 2024, 56
  • [43] Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy
    Avallone, Antonio
    Bimonte, Sabrina
    Cardone, Claudia
    Cascella, Macro
    Cuomo, Arturo
    ANTICANCER RESEARCH, 2022, 42 (10) : 4667 - 4678
  • [44] Chemotherapy-induced peripheral neuropathy: a review of recent findings
    Kim, Peggy Y.
    Johnson, Carrie E.
    CURRENT OPINION IN ANESTHESIOLOGY, 2017, 30 (05) : 570 - 576
  • [45] Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy
    Kanbayashi, Yuko
    Inagaki, Megumi
    Ueno, Hiroshi
    Hosokawa, Toyoshi
    MEDICAL ONCOLOGY, 2017, 34 (08)
  • [46] Management options for established chemotherapy-induced peripheral neuropathy
    Pachman, Deirdre R.
    Watson, James C.
    Lustberg, Maryam B.
    Wagner-Johnston, Nina D.
    Chan, Alexandre
    Broadfield, Larry
    Cheung, Yin Ting
    Steer, Christopher
    Storey, Dawn J.
    Chandwani, Kavita D.
    Paice, Judith
    Jean-Pierre, Pascal
    Oh, Jeong
    Kamath, Jayesh
    Fallon, Marie
    Strik, Herwig
    Koeppen, Susanne
    Loprinzi, Charles L.
    SUPPORTIVE CARE IN CANCER, 2014, 22 (08) : 2281 - 2295
  • [47] Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy
    Magnowska, Magdalena
    Izycka, Natalia
    Kapola-Czyz, Joanna
    Romala, Anna
    Lorek, Jakub
    Spaczynski, Marek
    Nowak-Markwitz, Ewa
    GINEKOLOGIA POLSKA, 2018, 89 (04) : 200 - 204
  • [48] Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)
    Han, Yaqin
    Smith, Maree T.
    FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [49] The search for treatments to reduce chemotherapy-induced peripheral neuropathy
    Pachman, Deirdre R.
    Loprinzi, Charles L.
    Grothey, Axel
    Ta, Lauren E.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (01) : 72 - 74
  • [50] A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy
    Li, K.
    Giustini, D.
    Seely, D.
    CURRENT ONCOLOGY, 2019, 26 (02) : E147 - E154